Enaex S.A (ENAEX) - Total Liabilities

Latest as of March 2026: CL$1.11 Billion CLP ≈ $1.24 Million USD

Based on the latest financial reports, Enaex S.A (ENAEX) has total liabilities worth CL$1.11 Billion CLP (≈ $1.24 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Enaex S.A to track the company's year-over-year net asset growth rate.

Enaex S.A - Total Liabilities Trend (2014–2025)

This chart illustrates how Enaex S.A's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Enaex S.A generate to measure how efficiently the company converts operating cash flow to free cash.

Enaex S.A Competitors by Total Liabilities

The table below lists competitors of Enaex S.A ranked by their total liabilities.

Company Country Total Liabilities
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
India Rs6.05 Billion
Nelnet Inc
NYSE:NNI
USA $10.57 Billion
BW LPG Ltd
OL:BWLPG
Norway Nkr1.32 Billion
GZ Port
SHG:601228
China CN¥29.89 Billion
Viohalco S.A
BR:VIO
Belgium €-2.36 Billion
Apeloa Pharmaceutical Co Ltd
SHE:000739
China CN¥5.68 Billion
Guosheng Financial Holding Inc
SHE:002670
China CN¥37.34 Billion
Hui Lyu Ecological Technology Groups Co Ltd
SHE:001267
China CN¥1.88 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Enaex S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Enaex S.A market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.78 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.09 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.50 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Enaex S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Enaex S.A (2014–2025)

The table below shows the annual total liabilities of Enaex S.A from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 CL$1.12 Billion
≈ $1.25 Million
+13.63%
2024-12-31 CL$981.44 Million
≈ $1.10 Million
-3.81%
2023-12-31 CL$1.02 Billion
≈ $1.14 Million
+6.14%
2022-12-31 CL$961.24 Million
≈ $1.07 Million
-15.32%
2021-12-31 CL$1.14 Billion
≈ $1.27 Million
+73.46%
2020-12-31 CL$654.43 Million
≈ $731.88K
+19.03%
2019-12-31 CL$549.81 Million
≈ $614.87K
+1.65%
2018-12-31 CL$540.88 Million
≈ $604.89K
+3.95%
2017-12-31 CL$520.35 Million
≈ $581.93K
+2.00%
2016-12-31 CL$510.15 Million
≈ $570.52K
-6.07%
2015-12-31 CL$543.10 Million
≈ $607.37K
+79.64%
2014-12-31 CL$302.33 Million
≈ $338.11K
--

About Enaex S.A

SN:ENAEX Chile Specialty Chemicals
Market Cap
$3.43 Billion
CL$3.07 Trillion CLP
Market Cap Rank
#4470 Global
#17 in Chile
Share Price
CL$24960.00
Change (1 day)
+0.00%
52-Week Range
CL$18768.00 - CL$25117.00
All Time High
CL$25117.00
About

Enaex S.A., together its subsidiaries, produces and sells explosives in Chile, Argentina, Peru, Brazil, South Africa, Australia, and internationally. The company offers ammonium nitrate; non-explosive fracturer; bulk explosives, including heavy anfo pumpable and auger, pumpable emulsions with small diameter, and aquagels; emulsions and boosters; and initiation systems, such as conventional and el… Read more